Negative
A reported negative result is associated with a lower likelihood of Alzheimer's pathology relative to the validation framework.
RESEARCH AND CLINICAL CONTEXT
Science Behind Alzheimer's Biomarker Insight
ALZ Blood Test is centered on plasma p-Tau217, a blood-based biomarker that can add amyloid-related context to cognitive evaluation. Supporting validation materials and the white paper summarize how p-Tau217 fits alongside other biomarkers within a broader clinical assessment.
Why p-Tau217 Matters
Alzheimer's disease is associated with amyloid plaque deposition and tau pathology. Plasma p-Tau217 has emerged as a practical biomarker because reported blood-based measurements correlate with amyloid PET findings and can help add biological context to cognitive evaluations.
Compared with more invasive or complex pathways, a blood draw may offer a more accessible way to begin gathering biomarker information. It is intended to complement, not replace, clinical examination, imaging, and other diagnostic tools.
- Provides blood-based biomarker insight relevant to amyloid-related pathology.
- Fits more easily into routine clinic workflows than invasive collection methods.
- Should be interpreted only within the full clinical context.
What the validation summary covers
The validation sheet summarizes clinical performance, reference range, assay interval, precision, linearity, stability, and interference using the reported study data for plasma p-Tau217.
The white paper places p-Tau217 in context with GFAP, Nf-L, and Aβ42/40 to show how different biomarkers can contribute distinct information within Alzheimer's evaluation and differential assessment.
Validation Highlights
The technical summary describes a clinically characterized cohort and reported PET-aligned interpretation thresholds intended to support clinician review.
Clinical Performance
The reported clinical cohort included dementia, mild cognitive impairment, normal cognition, and other diagnoses, with amyloid PET used as the reference comparator for performance assessment.
Interpretation Thresholds
The validation summary reports thresholds at ≤ 0.34 ng/L, 0.34 to 0.63 ng/L, and > 0.63 ng/L to support negative, intermediate, and positive result categories.
Analytical Workup
Supporting materials summarize assay interval, precision, admixture linearity, sample stability, and interference testing performed under reported CLSI-aligned laboratory methods.
Interpretation Framework
Reported result categories are meant to support decision-making, not confirm a diagnosis.
Broader Biomarker Landscape
The white paper also reviews additional biomarkers that can contribute different clinical perspectives alongside p-Tau217.
p-Tau217
p-Tau217 is the primary biomarker highlighted for amyloid PET-aligned performance and Alzheimer's-related tau pathology context.
GFAP
GFAP reflects astrocyte activation and may add useful differential context across a range of central nervous system conditions, including neurodegenerative disease.
Nf-L
Nf-L is a nonspecific marker of axonal injury and neurodegeneration that may help characterize broader neurological burden rather than Alzheimer's pathology alone.
Aβ42/40
The Aβ42/40 ratio is used to assess amyloid plaque biology and can complement other biomarkers when amyloid-focused context is clinically relevant.
Explore Clinical Materials
Review the white paper, validation sheet, and sample report for more detail on performance characteristics, biomarker context, and result presentation.